Diurnal is now Neurocrine UK
Founded in 2004, DIURNAL®, a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency.
Diurnal is dedicated to developing new treatments to aid lifelong treatment for rare and chronic endocrine conditions
Diurnal is committed to transparency in its interactions. Diurnal commits to following the Association of British Pharmaceutical Industry (ABPI) Code of Practice which has clear requirements for transparency.
Diurnal is a rapidly growing global specialty pharmaceutical company with a highly integrated and very committed team. We're always looking for talented individuals who share our vision. Visit this section to view our current opportunities.
A limited number of awards is available each year, and all applications will be judged objectively by an independent panel.
Neurocrine is committed to transparency in its interactions. Neurocrine commits to following the Association of British Pharmaceutical Industry (ABPI) Code of Practice which has clear requirements for transparency. Neurocrine has published details of its transfers of value required under the ABPI Code on the ABPI website and below. Disclosures prior to 2025 are reported under the legacy name Diurnal.
Where individual countries have other transparency regulations, Neurocrine also complies with the EFPIA through this route.
Neurocrine is committed to transparency in clinical trials and publishes the protocols and results of its clinical trials on the website www.clinicaltrials.gov